Nippon India Pharma Fund

SectoralDirect and Regular plans, Growth and IDCW options

Data as on 30-10-2026

Nippon India Pharma Fund is a Sectoral fund run by Nippon India Mutual Fund. On 30-09-2026, it managed ₹9,166 Cr of investors' money. In the 3 years to 30-10-2026, its Direct plan returned 18.6% a year and its Regular plan returned 17.5% a year. Its benchmark, BSE Healthcare TRI, returned 23.0% a year over the same 3 years.

NAV (Direct plan): ₹625.46; ▲ 0.52%30-10-2026
NAV (Regular plan): ₹555.24; ▲ 0.52%30-10-2026
Expense ratio: 0.99%Direct1.85%Regular; 0.99%; A year
Riskometer: Very High; Set by the fund house
3 year return: 18.6%Direct17.5%Regular; 18.6%; A year

Nippon India Pharma Fund NAV Today

NAV on 30-10-2026: Direct Plan Growth ₹625.46 (up 0.52% that day); Regular Plan Growth ₹555.24 (up 0.52% that day).

This fund (Direct plan)

₹625.4566

Nippon India Pharma Fund Returns vs BSE Healthcare TRI

Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.

Trailing returns
Period	1M	3M	6M	1Y	3Y	5Y	10Y
This fund (Direct)	−0.76%	−2.52%	+7.84%	+9.05%	+18.56%	+14.19%	+15.18%
This fund (Regular)	−0.82%	−2.73%	+7.38%	+8.10%	+17.50%	+13.17%	+14.16%
BSE Healthcare TRI	+0.24%	−0.99%	+12.80%	+12.37%	+23.01%	+15.61%	+12.48%
Sectoral average	−1.70%	−4.49%	+2.30%	−0.58%	+15.61%	+14.51%	+14.77%
Best in Sectoral	+7.03%	+2.10%	+17.99%	+19.53%	+21.77%	+18.38%	+16.60%
Worst in Sectoral	−7.36%	−8.92%	−7.57%	−9.47%	+9.87%	+10.82%	+12.21%
Rank in Sectoral	6/20	7/19	6/19	3/17	2/9	4/6	2/5

Category rows compare the Direct plans of 20 Sectoral funds. Rank 1 is the highest return.

Nippon India Pharma Fund Year-wise Returns

Return of each calendar year
Year	Direct	Regular	BSE Healthcare TRI
2026to date	+9.76%	+8.98%	+15.08%
2025	−2.46%	−3.34%	−2.72%
2024	+35.26%	+34.04%	+44.30%
2023	+40.36%	+39.15%	+37.97%
2022	−9.06%	−9.90%	−11.50%
2021	+25.12%	+23.93%	+21.54%

Nippon India Pharma Fund Rolling Returns

The return of every holding period in the fund's history, not only the one that ends today

Rolling returns

Each point is the yearly return of one 3-year holding period, plotted on the day it ended. There are 2,666 periods, one for each trading day from 04-01-2016 to 30-10-2026.

−10%0%10%20%30%40%

Nov 2013
to
Nov 2016Sept 2015
to
Sept 2018Jul 2017
to
Jul 2020May 2019
to
May 2022Mar 2021
to
Mar 2024Dec 2022
to
Dec 2025

Nippon India Pharma Fund (Direct)BSE Healthcare TRI

Every holding period at a glance

Period	Periods	Median	Lowest	Highest	With a loss	Benchmark median	Beat benchmark
1 year	3,154	13.1%	−15.1%	90.7%	23%	11.5%	76%
2 years	2,912	15.0%	−11.1%	53.2%	6%	12.8%	79%
3 years	2,666	19.9%	−1.3%	32.2%	1%	17.0%	82%
5 years	2,173	16.7%	0.0%	32.1%	0%	11.3%	94%
7 years	1,684	18.2%	9.5%	24.1%	0%	12.1%	100%
10 years	941	16.1%	13.1%	18.8%	0%	11.9%	100%

Every SIP holding period at a glance

Period	Periods	Median	Lowest	Highest	With a loss	Benchmark median	Beat benchmark
1 year	154	12.2%	−19.7%	81.4%	23%	7.6%	76%
2 years	142	11.9%	−11.4%	59.3%	14%	12.4%	77%
3 years	130	16.5%	−3.9%	42.9%	5%	14.1%	79%
5 years	106	18.0%	0.8%	29.7%	0%	15.2%	78%
7 years	82	18.9%	5.3%	26.4%	0%	14.6%	94%
10 years	46	18.4%	13.2%	21.1%	0%	15.9%	100%

Lumpsum: the yearly rate (CAGR) from the NAV on a period's first day to the NAV on its last. SIP: the XIRR of the monthly instalments and their value on the last day. "With a loss" counts the periods that ended below the money put in. "Beat benchmark" counts the periods in which the fund did better than BSE Healthcare TRI over the same days. Past returns do not promise future returns.

Nippon India Pharma Fund Risk

How much it swings, and the falls an investor had to sit through

Risk and return

Measure	Nippon India Pharma Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+9.05%	+12.37%
Standard deviation	12.27%	13.56%
Sharpe ratio	0.31	0.53
Sortino ratio	0.45	0.77
Maximum drawdown	−9.6% (23-10-2026)	−9.9% (23-10-2026)
Beta	0.87	1.00
Alpha	−2.40%	0.00%

From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Measure	Nippon India Pharma Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+18.56%	+23.01%
Standard deviation	12.96%	14.12%
Sharpe ratio	0.97	1.20
Sortino ratio	1.39	1.71
Maximum drawdown	−14.7% (28-02-2025)	−16.2% (28-02-2025)
Beta	0.88	1.00
Alpha	−2.50%	0.00%

From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Measure	Nippon India Pharma Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+14.19%	+15.61%
Standard deviation	12.88%	13.97%
Sharpe ratio	0.65	0.70
Sortino ratio	0.93	1.00
Maximum drawdown	−18.7% (17-06-2022)	−19.6% (17-06-2022)
Beta	0.89	1.00
Alpha	−0.35%	0.00%

From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Measure	Nippon India Pharma Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+15.18%	+12.48%
Standard deviation	15.46%	16.56%
Sharpe ratio	0.63	0.43
Sortino ratio	0.92	0.60
Maximum drawdown	−21.2% (23-03-2020)	−31.6% (23-03-2020)
Beta	0.90	1.00
Alpha	+3.44%	0.00%

From daily NAVs, 28-10-2016 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Measure	Nippon India Pharma Fund (Direct)This fund	BSE Healthcare TRI
Return (CAGR)	+17.18%	+14.72%
Standard deviation	15.19%	16.65%
Sharpe ratio	0.73	0.52
Sortino ratio	1.06	0.73
Maximum drawdown	−24.0% (29-05-2017)	−38.8% (23-03-2020)
Beta	0.85	1.00
Alpha	+3.72%	0.00%

From daily NAVs, 02-01-2013 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.

Drawdowns

How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.

−40%−30%−20%−10%0%

2014201620182020202220242026

Nippon India Pharma Fund (Direct)BSE Healthcare TRI

	Worst fall	High before it	Bottom	Back at the high	Time to climb back	Below its high today
Nippon India Pharma Fund (Direct)	−24.0%	30-10-2015	29-05-2017	17-08-2018	15 months	−4.3%
BSE Healthcare TRI	−38.8%	08-04-2015	23-03-2020	31-07-2020	4 months	−3.8%

From the Direct plan's daily NAV since 02-01-2013, adjusted for unit splits, and BSE Healthcare TRI over the same days. "Time to climb back" runs from the bottom to the first day back at the old high.

Nippon India Pharma Fund vs Other Sectoral Funds

The five Sectoral funds with the best three year return, and this fund. Direct plans.

Fund name	Rank	AUM (Cr)	Exp. ratio	1Y return	3Y return	3Y alpha	3Y beta	3Y Sharpe	3Y Sortino
DSP Healthcare Fund	1/9	3,750	0.76%	+15.40%	+21.77%	+2.89%	0.77	1.25	1.77	Compare
Nippon India Pharma Fund	2/9	9,166	0.99%	+9.05%	+18.56%	−2.50%	0.88	0.97	1.39
Bandhan Transportation and Logistics Fund	3/9	771	1.07%	−1.82%	+17.11%	+1.71%	0.84	0.69	0.97	Compare
Nippon India Power & Infra Fund	4/9	7,867	1.11%	−2.17%	+16.41%	+2.80%	0.97	0.59	0.78	Compare
Invesco India Financial Services Fund	5/9	1,789	0.96%	−2.22%	+15.03%	+5.53%	0.93	0.55	0.77	Compare

AUM is each fund's size at the end of its last reported month, from its own portfolio file. We calculate the risk ratios from daily NAVs over the last three years. The risk-free return is what NSE's overnight rate index earned over the same years. Alpha and beta compare each fund with its own benchmark's TRI. "--" means we have no figure: for alpha and beta, no daily series for that benchmark.

Nippon India Pharma Fund Expense Ratio and Costs

What each plan charges a year, in force from 14-10-2026

Plan	Base expense ratio	Brokerage	Transaction costs	Levies and GST	Total expense ratio	Sectoral median	Cost rank (1 = cheapest)
Direct	0.79%	0.02%	0.00%	0.18%	0.99%	1.07%	4/20
Regular	1.52%	0.02%	0.00%	0.31%	1.85%	2.51%	1/20

The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file. Cost rank: where this plan comes when the Sectoral funds' plans of the same type are sorted from the lowest total expense ratio to the highest.

Direct vs Regular: what the gap cost

Both plans own the same portfolio, so the difference in what they earned is the Regular plan's extra cost, taken out of its NAV.

Over the last	Regular	Direct	Direct earned more by	₹1 lakh became (Regular)	₹1 lakh became (Direct)
1 year	8.10%	9.05%	0.95%	₹1,08,100	₹1,09,050
3 years	17.50%	18.56%	1.06% a year	₹1,62,223	₹1,66,654
5 years	13.17%	14.19%	1.02% a year	₹1,85,634	₹1,94,151
10 years	14.16%	15.18%	1.02% a year	₹3,75,958	₹4,10,933

Returns over more than 1 year are a rate a year (CAGR). ₹1 lakh invested once at the start of each period, valued on the last NAV.

Nippon India Pharma Fund SIP Calculator

What a one-time or monthly investment in this fund would be worth today, from its own NAV history

Growth of an investment

Every month₹

Step up each year

PeriodFor

₹10,000 on the first trading day of every month, from 02-01-2013 to 30-10-2026: 166 instalments, ₹16,60,000 in all.

Investment	Invested	Value now	Gain	Return a year
Direct planNippon India Pharma Fund (Direct)	₹16,60,000	₹58,91,410	₹42,31,410	16.8%
Regular planNippon India Pharma Fund (Regular)	₹16,60,000	₹54,35,183	₹37,75,183	15.8%
BSE Healthcare TRI	₹16,60,000	₹50,28,835	₹33,68,835	14.8%
Category averageCategory average, 20 Sectoral funds	₹16,60,000	₹59,77,795	₹43,17,795	17.0%

₹0₹20.0 L₹40.0 L₹60.0 L₹80.0 L

2014201620182020202220242026

Direct planNippon India Pharma Fund (Direct)Regular planNippon India Pharma Fund (Regular)BSE Healthcare TRICategory averageCategory average, 20 Sectoral fundsAmount invested

From each plan's published NAV (Growth option), the benchmark's TRI and the category average, over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.

Nippon India Pharma Fund Asset Allocation

Asset allocation as on 30-09-2026

What the fund holds

97.3%Equity

Asset	Fund	Category
Equity	97.3%	95.6%
Cash and others	2.7%	3.7%

Market cap of stocks

Market cap	Fund	Category
Large Cap	29.7%	44.1%
Mid Cap	39.0%	21.8%
Small Cap	28.0%	26.9%
Not on AMFI's list	0.5%	2.3%

Share of the whole fund. Category: the average of the Sectoral funds that hold stocks. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.

Nippon India Pharma Fund Sector Allocation

Sector allocation of the fund's stocks as on 30-09-2026

Largest sectors

Pharmaceuticals & Biotechnology74.0%
Healthcare Services20.3%
Retailing2.5%
Healthcare Equipment & Supplies0.5%

Sector changes

Sector	July 2026	August 2026	September 2026	Change
Pharmaceuticals & Biotechnology	73.5%	74.0%	74.0%	+0.5%
Healthcare Services	21.1%	21.1%	20.3%	−0.8%
Retailing	2.7%	2.5%	2.5%	−0.2%
Healthcare Equipment & Supplies	--	0.4%	0.5%	--

Each sector's share of the fund at the end of each month. The five largest sectors of September 2026. Change: from July 2026 to September 2026, in % of the fund.

Nippon India Pharma Fund Portfolio Holdings

As on 30-09-2026 · 36 holdings · from the fund house's monthly portfolio

Holdings	Sector	Weight%	1M change
Sun Pharmaceutical Industries Limited	Pharmaceuticals & Biotechnology	11.71%	0.0%
Divi's Laboratories Limited	Pharmaceuticals & Biotechnology	7.10%	0.0%
Lupin Limited	Pharmaceuticals & Biotechnology	6.17%	0.0%
Cipla Limited	Pharmaceuticals & Biotechnology	6.01%	0.0%
Dr. Reddy's Laboratories Limited	Pharmaceuticals & Biotechnology	5.45%	0.0%
Apollo Hospitals Enterprise Limited	Healthcare Services	4.89%	0.0%
Mankind Pharma Limited	Pharmaceuticals & Biotechnology	4.38%	0.0%
Sai Life Sciences Limited	Pharmaceuticals & Biotechnology	3.92%	−7.8%
Ajanta Pharma Limited	Pharmaceuticals & Biotechnology	3.61%	0.0%
GlaxoSmithKline Pharmaceuticals Limited	Pharmaceuticals & Biotechnology	3.11%	0.0%
IPCA Laboratories Limited	Pharmaceuticals & Biotechnology	2.87%	0.0%
Max Healthcare Institute Limited	Healthcare Services	2.70%	0.0%
Vijaya Diagnostic Centre Limited	Healthcare Services	2.62%	0.0%
MedPlus Health Services Limited	Retailing	2.53%	0.0%
Gland Pharma Limited	Pharmaceuticals & Biotechnology	2.53%	0.0%
Abbott India Limited	Pharmaceuticals & Biotechnology	2.32%	+0.5%
Piramal Pharma Limited	Pharmaceuticals & Biotechnology	2.24%	0.0%
Thyrocare Technologies Limited	Healthcare Services	2.24%	0.0%
Dr. Lal Path Labs Limited	Healthcare Services	2.17%	0.0%
Alkem Laboratories Limited	Pharmaceuticals & Biotechnology	1.82%	0.0%
Aurobindo Pharma Limited	Pharmaceuticals & Biotechnology	1.65%	0.0%
Narayana Hrudayalaya Limited	Healthcare Services	1.61%	0.0%
Suraksha Diagnostic Limited	Healthcare Services	1.51%	0.0%
Syngene International Limited	Healthcare Services	1.40%	0.0%
Emcure Pharmaceuticals Limited	Pharmaceuticals & Biotechnology	1.36%	0.0%
Pfizer Limited	Pharmaceuticals & Biotechnology	1.35%	0.0%
Akums Drugs and Pharmaceuticals Limited	Pharmaceuticals & Biotechnology	1.21%	0.0%
Anthem Biosciences Limited	Pharmaceuticals & Biotechnology	1.19%	0.0%
Fortis Healthcare Limited	Healthcare Services	1.13%	0.0%
Biocon Limited	Pharmaceuticals & Biotechnology	1.01%	0.0%
Sanofi India Limited	Pharmaceuticals & Biotechnology	1.00%	0.0%
Sanofi Consumer Healthcare India Limited	Pharmaceuticals & Biotechnology	0.89%	0.0%
Molbio Diagnostics Limited	Healthcare Equipment & Supplies	0.54%	0.0%
Indoco Remedies Limited	Pharmaceuticals & Biotechnology	0.48%	−8.4%
AstraZeneca Pharma India Limited	Pharmaceuticals & Biotechnology	0.42%	0.0%
Concord Biotech Limited	Pharmaceuticals & Biotechnology	0.17%	0.0%

Nippon India Pharma Fund Stocks Bought and Sold

All changes are between August 2026 and September 2026

Stocks bought and sold in September 2026

Sai Life Sciences Limited	Reduced	−7.8%	3.92%
Abbott India Limited	Added	+0.5%	2.32%
Indoco Remedies Limited	Reduced	−8.4%	0.48%

A change is counted by the number of shares the fund holds, not by price. A stock can become a smaller part of the fund in a month when the fund bought more of it, if its price fell. Debt papers are left out.

What Nippon India Pharma Fund bought and sold

Nippon India Pharma Fund Portfolio Overlap

Funds with the most similar portfolios, across every fund house and category

Fund	Overlap	Holdings in common
Aditya Birla Sun Life Pharma and Healthcare FundThematic · Aditya Birla Sun Life	63.8%	28	Compare
Mirae Asset Nifty 500 Healthcare ETFETF · Mirae Asset	61.2%	26	Compare
Motilal Oswal BSE Healthcare ETFETF · Motilal Oswal	59.5%	34	Compare
Bandhan BSE Healthcare Index FundIndex · Bandhan	59.3%	34	Compare
ITI Pharma and Healthcare FundThematic · ITI	57.6%	20	Compare
DSP Nifty Healthcare ETFETF · DSP	56.0%	15	Compare
DSP Nifty Healthcare Index FundIndex · DSP	56.0%	15	Compare
Axis NIFTY Healthcare ETFETF · Axis	56.0%	15	Compare

Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.

Nippon India Pharma Fund Overview

Fund facts from the scheme summary document, as on 16-10-2026

Expense ratio (Direct): 0.99%
Expense ratio (Regular): 1.85%
Category: Sectoral
Risk: Very High
Benchmark: BSE Healthcare TRI
Launch date: 05-06-2004
Minimum investment: ₹5,000
Minimum additional investment: ₹1,000
AUM: ₹9,166.40 Cr (30-09-2026)
Lock in: None
Scheme code (Direct): 118759
ISIN (Direct): INF204K01I50
Scheme code (Regular): 102431
ISIN (Regular): INF204K01968
NAV history: From 02-01-2013, 13.8 years

Exit load: Exit load of 1% if redeemed within 1 month.

Tax on Nippon India Pharma Fund returns

Nippon India Pharma Fund is taxed as an equity fund: 65% or more of it is in Indian stocks.
Units sold within 1 year: the gain is taxed at 20%.
Units held longer: gains above ₹1.25 lakh in a financial year, across all your equity funds and shares, are taxed at 12.5%.
IDCW (dividend) payouts are added to your income and taxed at your slab rate.
A stamp duty of 0.005% is deducted when you invest.

Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.

All plans and options

Plan	Option	NAV	As on
direct	Bonus	₹625.4566	30-10-2026
direct	Growth	₹625.4566	30-10-2026
direct	IDCW	₹171.1742	30-10-2026
regular	Bonus	₹555.2364	30-10-2026
regular	Growth	₹555.2364	30-10-2026
regular	IDCW	₹119.90	30-10-2026

About Nippon India Pharma Fund

Nippon India Pharma Fund is a mutual fund from Nippon India Mutual Fund. Its category is Sectoral. It was launched on 05-06-2004. Its benchmark is BSE Healthcare TRI. At the end of September 2026 it held 36 securities.

Fund Manager

Sailesh Raj Bhan
Fund manager of Nippon India Pharma Fund, since 01-06-2004

See all funds of Nippon India Mutual Fund

AUM change

September 2026: ₹9,166.40 Cr; −3.30% from August 2026
August 2026: ₹9,479.08 Cr; +2.16% from July 2026
July 2026: ₹9,279.11 Cr; +2.60% from June 2026

AUM moves with money invested or taken out, and with the value of what the fund holds.

Compare Nippon India Pharma Fund with Other Funds

Returns, risk, costs and the stocks they share, side by side

Nippon India Pharma vs DSP HealthcareSectoral
Nippon India Pharma vs Bandhan Transportation and LogisticsSectoral
Nippon India Pharma vs Nippon India Power & InfraSectoral
Nippon India Pharma vs Invesco India Financial ServicesSectoral
Nippon India Pharma vs Aditya Birla Sun Life Pharma and Healthcare63.8% overlap
Nippon India Pharma vs Mirae Asset Nifty 500 Healthcare ETF61.2% overlap
Nippon India Pharma vs Motilal Oswal BSE Healthcare ETF59.5% overlap
Nippon India Pharma vs Bandhan BSE Healthcare Index59.3% overlap

Compare with any other fund

Frequently Asked Questions for Nippon India Pharma Fund

What is the current NAV of Nippon India Pharma Fund?

The Direct plan NAV is ₹625.4566. The Regular plan NAV is ₹555.2364, as on 30-10-2026.

What are the returns of Nippon India Pharma Fund?

The Direct plan returned +9.05% in 1 year, +18.56% a year over 3 years, +14.19% a year over 5 years. The Regular plan returned +8.10% in 1 year, +17.50% a year over 3 years, +13.17% a year over 5 years. These figures are as on 30-10-2026.

What is the expense ratio of Nippon India Pharma Fund?

The Direct plan charges 0.99% a year. The Regular plan charges 1.85% a year. This is the figure the fund house reported to AMFI, in force from 14-10-2026.

What is the AUM of Nippon India Pharma Fund?

Nippon India Pharma Fund managed ₹9,166.40 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.

What are the top holdings of Nippon India Pharma Fund?

At the end of September 2026 the largest holdings were SUNPHARMA (11.71%), DIVISLAB (7.10%), LUPIN (6.17%), CIPLA (6.01%), DRREDDY (5.45%). The fund held 36 securities in all.

What did Nippon India Pharma Fund buy and sell in September 2026?

It added shares in 1. It reduced 2.

How do I invest in Nippon India Pharma Fund?

Through Nippon India Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. The first investment is at least ₹5,000. You can invest once or through a monthly SIP.

Who is the fund manager of Nippon India Pharma Fund?

Sailesh Raj Bhan (since 01-06-2004).

Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document, as on 16-10-2026.

This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.